Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
about
Neoadjuvant endocrine therapy in breast cancer: current role and future perspectivesA phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancerInternational Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.Advances in the approach to novel drug clinical development for breast cancer.Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French
P2860
Q26773012-A9FCF28A-9873-4E63-B341-D41F5831E0F9Q33407185-0E979ACA-F255-472B-98A3-C6B9A39C88FAQ34991926-8DE1BCAD-F4B4-42C9-A835-ABA8C3791FD3Q37228051-F5E6E31D-4301-48D6-A9C0-1541C185245CQ37376167-B17E4839-95F4-4C0D-8F49-DAD99F938A50Q37590339-55F7D800-4CA8-4541-BB6B-3EF1317CC362Q38206546-26BCD4F2-D656-4D2F-A1DF-C2B09BD985B1Q38464311-C73CFA6A-70A1-4262-92F2-4356BB8910E8Q46216934-8BBEF37C-63A8-4DFB-8A53-C98B0DFFF843Q51697267-ED3017C5-7DE5-4A82-B969-AC17EC66073B
P2860
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
@ast
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
@en
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
@nl
type
label
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
@ast
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
@en
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
@nl
prefLabel
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
@ast
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
@en
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
@nl
P2093
P2860
P1476
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
@en
P2093
Cynthia Ma
Jingqin Luo
Matthew James Ellis
Rodrigo Goncalves
Vera Suman
P2860
P304
P356
10.1038/NRCLINONC.2012.21
P407
P577
2012-02-28T00:00:00Z